ABSTRACT Serum angiotensin I converting enzyme (ACE) and lysozyme have been measured in 23 controls, 115 patients with sarcoidosis, and 64 with other chest diseases. Both enzymes were significantly raised in sarcoidosis. ACE was raised above the normal range in 21 of 72 (29%) patients with definite sarcoidosis and in 17 of 38 (45%) of those who were untreated and seen within one year of presentation. The rise discriminated usefully between those with stable and progressive disease (5% and 62% respectively). Lysozyme was raised in 50 of 72 (69%) patients with sarcoidosis but also in 11 of 54 (20%) patients with other chest diseases. Discrimination between stable and progressive disease was useful only if very high levels were considered. Five patients had serial measurements after treatment with oral steroids and showed a progressive fall in levels of both enzymes, but patients with other diseases also showed a significant fall within the normal range when so treated. Measurement of these enzymes may help in the management of some cases of sarcoidosis, but results require critical interpretation.
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Problems in managing sarcoidosis include diagnosis in atypical cases and the assessment of activity in chronic disease. Lieberman (1975, 1976) reported that serum angiotensin I converting enzyme (ACE) was raised in sarcoidosis, and its measurement was claimed to be useful for diagnosis and following the effects of treatment. These findings were supported by Ashutosh and Keighley (1976) , Fanburg et al (1976) , and Simonowitz et al (1977) , but considerable overlap with normal values was found by Silverstein et al (1976) , who also reported raised levels in sarcoid lymph nodes.
Serum lysozyme is also raised in sarcoidosis (Pascual et al, 1973) , though it may be raised in other infections and neoplastic diseases. Its measurement has been claimed to be useful in following the activity of sarcoidosis (Selroos and Klockars, 1977) . When both enzymes are measured in the same patients, positive correlation is significant in sarcoidosis but not in controls (Silverstein et al, 1977 The difficulties of determining the time of onset of sarcoidosis are recognised. The time of presentation of disease was taken as the date of first symptoms or finding of abnormal chest radiograph. The patients were divided into those with onset less than one year before assessment, who were considered to have "acute" disease, and those with disease of longer standing.
Forty-seven patients with pulmonary infiltrates or fibrosis were divided into those with stable or progressive disease by clinical, radiographic, and physiological assessment. Seventeen patients were found to have unequivocal deterioration of the chest radiograph with regard to pulmonary infiltration when the immediately previous (three to 28 months) or subsequent (one to six months) films were compared blindly with those taken at the time of assessment. Five of these had an associated fall of carbon monoxide gas transfer (TLCO) of greater than 20% predicted. These patients were considered "progressive." None of those radiographically unchanged had changes of TLco as great as 20% predicted or had deteriorated symptomatically. These were considered "stable."
Sixty-four patients with various other diseases affecting the lungs were also investigated. They included patients with active post-primary pulmonary tuberculosis (eight), old pulmonary tuberculosis (four), cryptogenic fibrosing alveolitis (26), asthma (eight), and carcinoma of the bronchus (eight). Other diseases included Wegener's granulomatosis, eosinophilic granuloma, lymphosarcoma, and emphysema.
EFFECT OF STEROID TREATMENT
Five patients had serial measurements of both enzymes for up to 12 weeks. Nine patients with diseases other than sarcoidosis, and with normal enzyme levels initially, had second determinations up to one month after starting treatment with oral prednisone.
Venous blood was taken. Serum was separated within four hours and stored at -200C. ACE was measured by the method described by Cushman and Cheung (1971) as modified by Lieberman (1975) . This is based on the spectrophotometric measurements of hippuric acid released from benzoyl-glycyl-L-histidyl-L-leucine by ACE. 02 ml of serum are added to 0 1 ml of substrate solution (12 5 M hippuryl-L-histidyl-Lleucine in potassium phosphate-sodium chloride buffer at pH 8-3 prepared one day previously) and incubated at 370C for 45 minutes. The reaction is terminated by adding 0 3 ml of IM hydrochloric acid. The tubes are cooled at 40C for 10 minutes. 1-5 ml of ethyl acetate is added to each tube and vortex mixed for 15 seconds. The tubes are centrifuged at 2500 rpm for 15 minutes at 10°C. 1-0 ml of the upper solvent layer is pipetted into a tall tube, and heated on a hot plate at 1200C to dryness. After cooling, 1-0 ml of IM sodium chloride is added and vortex mixed for 15 seconds. A further 2-0 ml of IM sodium chloride is then added and mixed by inversion. The reconstituted extracts in M NaCl show a tendency to form turbid suspensions using this method. The variability of results, which has led to the assay being performed in triplicate (Fanburg et al, 1976) , may be related to this phenomenon. The problem can be overcome by passing each suspension through a 0 45 ,um membrane filter before spectrophotometric determination. The optical density of the extract, and of appropriate blanks, are measured at 228 nm using the ultraviolet lamp of a Pye Unicam SP 1800 spectrophotometer, ACE activity is defined as nanomoles of hippuric acid formed per minute under the assay conditions and expressed as units of ACE per ml serum.
Lysozyme was measured by the method of Litwack (1955) as modified by Firth (1976) 
Results

NORMAL RANGES
The normal range for ACE was 12-41 units and for lysozyme 0 9-2 6 units.
RESULTS IN SARCOIDOSIS
The numbers of patients in various groups, their means, one standard deviation, significance of differences from normals, number and percentage raised above the normal range are shown for ACE in table 1 and for lysozyme in table 2. Serum ACE was raised significantly in the groups of patients with definite sarcoidosis who were not on steroids. The numbers of patients with raised levels were rather small-29% of all patients with definite sarcoidosis and 45% of those untreated with steroids and seen within one year of presentation. ACE was raised in only one patient on steroids. The levels in those patients with BHL and erythema nodosum did not differ from those with BHL alone. Fewer (19%) of those patients without histological confirmation for the diagnosis had raised levels, but the same trends with regard to the duration of disease and steroid treatment were present. The highest level of ACE recorded was 81 units, twice the upper limit of the normal range. ACE was raised in one of 19 (5%) patients classified stable but in eight of 13 (62%) untreated progressive patients. This is significant when compared with the whole definite sarcoidosis group (X2=7-03, P<0-01).
Serum lysozyme was also raised significantly in the patients with definite sarcoidosis, and 69% had raised levels. This proportion varied little with time from presentation or in respect of steroid treatment. A similar proportion of those patients without histological support for the diagnosis had raised levels. Although the 13 untreated progressive patients all had raised levels, so did 11 of 19 (58%) untreated stable patients. If very high levels (greater than six SDs above the normal mean, 4 4 units) are considered, however, there were nine (69%) in the progressive group and three (16%) in the stable group. The highest level of lysozyme recorded was 12-8 units, about five times greater than the upper limit of normal.
RESULTS IN OTHER DISEASES
ACE was raised in two of 64 (4%) patients with chest diseases other than sarcoidosis. One of these had siderosilicosis and the other fibrosing alveolitis with progressive systemic sclerosis. Lysozyme was raised in 11 of 54 (20%) patients with other diseases. Serum ACE was significantly higher in those of the miscellaneous group as a whole who were untreated compared with those on steroids (1976) . The lower levels reported by Lieberman (1975) , and Ashutosh and Keighley (1976) , are due to an error in calculation that has been acknowledged by Lieberman (1976) . Varying levels of lysozyme have been reported in normal controls because of the use of different standards.
We confirm previous reports (Lieberman, 1975 (Lieberman, , 1976 Ashutosh and Keighley, 1976; Fanburg et Silverstein et al, 1976; Simonowitz et al, 1977 ) that serum ACE is raised in patients with sarcoidosis, particularly within one year of presentation. The investigation is less than ideal as a diagnostic test because, although there are very few positives in other diseases, the negative rate for all patients with definite sarcoidosis is over 70%, and the range of abnormality narrow. The rise of ACE does discriminate usefully between those classified by other criteria as having stable or progressive disease.
Serum lysozyme is also significantly raised in sarcoidosis, and the numbers with raised levels are greater than for ACE. The investigation is of little value diagnostically because of the numbers of positives in other diseases. It does not discriminate between stable and progressive disease, but the range of abnormality is greater than for ACE, and consideration of very high levels improves discrimination.
The suggestion that measurement of these enzymes is useful in following the effects of treat- (Lieberman, 1975; Ashutosh and Keighley, 1976; and Simonowitz et al, 1977) and the demonstration of a progressive fall within patients when started on steroids (Lieberman, 1976) . The assumption was that steroids have no direct effect. We have shown that levels of both enzymes fall significantly in patients with diseases in which the enzymes are not raised and with normal initial levels, suggesting that steroids do have a direct effect independent of any action on sarcoidosis. These influences cannot be distinguished, which complicates interpretation of serial measurements when treatment has been started or changed.
It is concluded that the rise of serum ACE or considerable rise of lysozyme does represent active sarcoidosis, though this is not excluded by normal levels. It should be emphasised that the disease is usually self-limiting and that demonstration of active disease does not necessarily indicate the 
